Image courtesy of Google Maps

A Cambridge biotech startup is joining the growing life science cluster in Boston’s Fenway neighborhood.

Strand Therapeutics, founded in 2017 by researchers from the MIT Synthetic Biology Center, leased 64,231 square feet at 20 Overland St. The firm has raised $66 million in venture capital funding to date, including a $52-million series, a round syndicated by Redmile Group, BeiGene Ltd., and Camford Capital in June 2021.

The 202,167-square-foot Overland Street building is owned by IQHQ Inc., a San Diego life science developer that’s planning a series of major life science developments in the Fenway, Brighton and Cambridge.

Strand Therapeutics, which has its current headquarters at 237 Putnam Ave. in Cambridge, did not respond to requests for comment. The Fenway lease runs for seven years, according to a Suffolk County Registry of Deeds filing.

IQHQ received approval from the Boston Planning and Development Agency in January for its 109 Brookline project, which will create 250,000 square feet of office and lab space in a new 10-story life science tower next to 20 Overland St.

IQHQ also is partnering with developer Meredith Management on the Fenway Center air rights project, including a pair of office-lab towers that will be built over the Massachusetts Turnpike.